Abstract Details

Title A Phase II Trial to Assess the Efficacy, Safety and Feasibility of 20% Subcutaneous Immunoglobulin in Patients with Myasthenia Gravis Exacerbation - Interim Analysis of Efficacy

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) (-)

Poster/Presentation
Number 176

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Zaeem A. Siddiqi, MD, PhD (University of Alberta Hospital) PRESENTER	Dr. Siddiqi has nothing to disclose.
	No disclosure on file
Derrick Blackmore (University of Alberta Hospital)	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��